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ABSTRACT
Sodium N-[(trimethylamineboryl)-carbonyl]-L-phenylalanine 2 and {N-[(trimethylamineboryl)-carbonyl]-L-
phenyaany-carbxyat}-bis-{N-[(trimethyaminebry)-carbny]-Lphenyaanne} dicopper (II) 3 were
successfully synthesized. The agents blocked L1210 Ieukemic cell DNA and RNA syntheses by inhibiting
multiple enzyme activities for nucleic acid synthess, e.g. PRPP amido transferase, IMP dehydrogenase, DNA
polymerase c, thymidine kinase, and TMP kinase. The copper (II) complex 3 demonstratedimproved ability
to inhibit L1210 partially purified DNA topoisomerase II compared to the parent compound whde the sodium
salt was inactive at 100 laM.
INTRODUCTION
N-[(Trimethylamineboryl)-carbonyl]-L-phenylalanine methyl ester 1 has been shown to be an effective
antineoplastic agent o. Mode of action studies in L1210 cells demonstrated that DNA and RNA syntheses were
inhibited. Enzyme activities including PRPP amido transferase, IMP dehydrogenase, and DNA polymerase ct
were significantly inhibited by the phenylalanine derivative 1. Preliminary studies with trimethy_lamine
carboxyborane have shown that whereas the amine borane derivatives are potent antineoplastic agents 2, metal
complexation of these agents with copper, cobalt, chromium, iron and zinc complexes, produced more potent
derivatives 3,4. Thus the following study involves comparison of the modes of action of the sodium salt and
the copper (II) complex ofN-[(trimethylamineboryl)-carbonyl]-L-phenylalanine in L 1210 cells.
MATERIALS AND METHODS
Chemistry
All chemicals were used as received from the manufacturer. Solvents were distilled prior to use.
Trimethylamine carboxyborane was provided by Boron Biologicals, Inc. (Raleigh, NC). N-
[(Trimethyl,amineboryl)-carbonyl]-L-phenylalanine methyl ester 1 was synthesized according to the method of
Sood et al.. All other chemicals used in syntheses were purchased from Aldrich Chemical Company
(Milwaukee, WI). A Perkin Elmer 1320 Infrared Spectrophotometer was used for infrared (IR) analyses. IR
spectra were obtained as KBr disks or as nujol mulls using sodium chloride plates. A Varian 300 MHz NMR
spectrometer was used to generate 1H-NMR spectra. Chemical shifts are relative to the external standard
tetramethylsilane (i 0). A Thomas-Hoover capillary melting point apparatus was used to determine
melting points, which were uncorrected. Elemental analyses were performed by M-H-W Laboratories
(Phoenix, AZ). Silica gel 60F 254 plates (silica gel on aluminum, Aldrich Chemical Company) were used
for thin layer chromatography.
Synthesis of Sodium N-[(trimethylamineboryl)-carbonyl]-L-phenylalanine (2):
N-[(Trimethylamineboryl)-carbonyl]-L-phenylalanine methyl ester 1 (1 g, 3.59 mmol) was suspended in 50
ml distilled water to which 3.6 ml of an 0.986 M aqueous NaOH solution (0.14 g, 3.59 mmol) was slowly
added while stirring. After 15 minutes, the reaction appeared to be complete by TLC analysis although small
amounts of an insoluble white solid are present. The white solid was removed by vacuum filtration and
solvent was removed under reduced pressure leaving a white hygroscopic solid. The white hygroscopic solid
was further purified by silica gel column chromatography using one void volume of ethyl acetate, followed by
ethyl acetate acetonitrile (1:1) until completed. Combined pure fractions yielded 486.8 mg (47%) of a white
hygroscopic solid; Rf=0.12 in 1:1 ethyl acetate/acetonitrile. 1H-NMR (DMSO-d6): i 7.16 (m,5H,C6H); i
6.57 (d, J= 9 Hz, 1H, NH); i 4.35 (dd, J 18, 9 Hz, 1H,CH); i 3.10 (dd J 13,4 Hz, 1H,CH2); fi 2.88 (dd,
J 13,4 Hz, 1H, CH3); i 2.60 (s, 9H,NMe3); 6 1.72 (m,2H,BH2); IR (cm’l)Nuiol 3450 VNH, 2380 VBH,
0 0 1575 VCONH; m.p. 95-97C (dec.). Calcd.: C, 54.57A; H, 7.05A; N, 9.79%. Found: C, 54.33%; H,
6.95%; N, 9.57%.
Synthesis of Tetrakis la {N [(trimethylamineboryl) earbonyl] L -phenylalanyl-earboxylato}- bis
-{N-[(trimethylamineboryl)-earbonyl] -L-phenylalanine} dieopper (II) (3):
A column (300 x 10 m.m) was packed with IR-120 cation exchange resin to a bed volume of 10 ml by the
method of McCubbins . The column packing was washed with water (D.I., 4 x 25 ml) then charged withVol. 5, No. 1, 1998 The Synthesis and Antitumor Activity ofthe Sodium Salt and Copper (II) Complex
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HC1 (1M, 4 x 25 ml). The column was washed with water (D.I., 25 ml) to remove the excess acid from the
packing. A solution of copper (II) chloride (1M, 4 x 25 ml) was allowed to pass through the column. This
was followed by washing the excess copper solution off of the column with water (D.I.) until sample eluent
gave a negative chloride test result using 1% AgNO3. The solvent in the column was changed from water to
MeOH by using a gradient, increasing the MeOH content by 10% each 25 ml until 25 ml 100% methanol
was eluted. Sodium N-[(trimethylamineboryl)-carbonyl]-L-phenylalanine (1) (100 rag) was dissolved in dry
MeOH (1 ml) and eluted through the column. After elution of approximately 10 ml of MeOH, the clear
mobile phase tumed blue. The solvent was removed by rotary evaporation, resulting in 84 mg (84% yield) of
a blue solid. 1H-NMR (CD3OD) 7.26 (m,30H, 6 C6H5); i 4.87 (m,6H, 6 NH); 3.36 (m, 6H, 6 CH);
2.72 (m, 12H, 6 CH2); i 2.60 (m, 54H, 6 NMe3); 6 2.10 (m, 12H, BH2); IR (cm’l)Nuiol: 3440 VNH, 2380
VBH, 1580 VCONH; m.p. 109-111C (dec.) Calcd.: C, 54.86%; H, 7.20%; N, 9.84%.-Found: C, 54.62%;
H, 6.96%; N, 9.61%.
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Scheme 1" The Synthesis of Derivatives of the Boronated Dipeptide N-[(Trimethylamineboryl)-carbonyl]-L-
phenylalanine Methyl Ester.
Cytotoxicity
Compounds 1 -3 were tested for cytotoxic activity by homogenizing drugs in a mg/ml solution in 0.05%
Tween 80/H20. These solutions were sterilized by passing them through an acrodisc (45 m). The
following cell lines were maintained by literature techniques o: murine L1210 lymphoid leukemia, rat UMR
106 osteosarcoma, human Tmolt3 acute lymphoblastic T cell leukemia, HeLa-S3 suspended cervical
carcinoma, HeLa solid cervical carcinoma, KB epidermoid nasopharynx, A431 epidermoid, carcinoma,
colorectal adenocarcinoma SW480, HCT-8 ileocecal adenocarcinoma, lung bronchogenic MB-9812, A549
lung carcinoma, and glioma HS683. Geran et al.’s protocol 7 was used to assess the suspended cell
cytotoxicity of the compounds and standards in each cell line. Cell numbers were determined by the trypan
blue exclusion technique. Solid tumor cytotoxicity was determined by Leibovitz et al. ’s method 7 utilizing
crystal violet/MeOH and read at 562 nm (Molecular Devices). Values for cytotoxicity were expressed as EDso
g/ml, i.e. the concentration of the compound inhibiting 50% of cell growth. A value of less than 4 tg/ml
was required for significant activity ofgrowth inhibition.
Incorporation Studies 6
Incorporation of labeled precursors into 3H-DNA, 3H-RNA and 3H-protein for 10 L1210 cells was obtained 8
at concentration of the agents at 25, 50 and 100M during 60 min incubations. The incorporation of
-glycine (53.0 mCi/mmol) into purines was obtained by the method of Cadman et al.9. Incorporation of
formate (53.0 mCi/mmol) into pyrimidines was determined by the method of Christopherson et al. 1.M.C. Miller, III, A. Sood et al. Metal-Based Drugs
Enzyme Assays
Inhibition of various enzyme activities was performed by first preparing the appropriate L1210 cell
homogenates or subcellular fractions, then adding the drug to be tested during the enzyme assay. For the
concentration response studies, inhibition of enzyme activity was determined at 25, 50 and 100 taM of
compounds 2 and 3 after 60 min incubations. DNA polymerase t activity was determined in cytoplasmic
extracts isolated by Eichler et al. ’s method l. The polymerase assay DNA polymerase o was described by
Sawada et al. 12 with 3H-TTP. Messenger-, ribosomal- and transfer-RNA polymerase enzymes were isolated
with different concentrations of ammonium sulfate; individual RNA polymerase activities were determined
using 3H -UTP 13,14. Ribonucleoside reductase activity was measured using 14C -CDP with dithioerythritol
15. The deoxyribonucleotides 14C -dCDP were separated from the ribonucleotides by TLC on PEI plates.
Thymidine, TMP and TDP kinase activities were determined using 3H -thymidine (58.3 mCi/mmol) in the
medium of Maley and Ochoa 16. Carbamyl phosphate synthetase activity was determined with the method of
Kalman et a/.17; citrulline was determined colorimetrically 18. Aspartate transcarbamylase activity was
18 r am as artate was determined measured using the incubation medium of Kalman et al. cab y p
colorimetrically by the method of Koritz et al. 19. Thymidylate synthetase activity was analyzed by Kampf et
al. ’s method 20. The 3H20 measured was proportional to the amount of TMP formed from 3H-dUMP.
Dihydrofolate reductase activity was determined by the spectrophotometric method of Ho et al.21. PRPP
amidotransferase activity was determined by Spassova et al. ’s method 22; IMP dehydrogenase activity was
analyzed with 8-14C-IMP (54 mCi/mmol) (Amersham, Arlington Heights, IL) after separating XMP on PEI
plates (Fisher Scientific) by TLC 23. Protein content was determined for the enzymatic assays by the Lowry
technique 24.
Table 2: Effects ofSodium N-[(Trimethylamineboryl)-carbonyl]-L-phenylalanine (2) on
L1210 Leukemia Cell Metabolism In Vitro Over 60 Min. Percent of Control (mean + s.d.)
(N=4)
Assay Control 25 tM 50M 1001aM
DNA synthesis 100+5a 94_+6 94_+5 52_+5"
RNA synthesis 100_+6b 82_+5 77_+6* 75_+4"
Protein synthesis 100_+5c 102_+6 99_+5 91_+5
DNA polymerase o 100+6d 69_+6* 58_+5* 49_+4*
rRNA polymerase 100_+4e 104_+6 94_+2 89_+4
mRNA polymerase 100+7f 99_+5 91_+3 68_+4"
tRNA polymerase 100_+7g 102_+6 102_+4 77_+5"
Ribonucleoside diphosphate reductase 100_+5h 111_+5 99_+5 96_+3
Dihydrofolatereductase 100_+5 127_+9 112_+5 88_+5
De novo purine synthesis 100+5J 42-+5* 29-+5* 28_+3*
PRPP amido transferase 100_+6k 84_+5 58_+4’ 51_+3 *
IMP dehydrogenase 100+51 51-+5’ 40-+4* 36-+4*
Carbamyl phosphate synthetase 100+7m 105_+7 98+5 95-+6
Aspartatetranscarbamylase 100-+6n 106+5 94_+6 92_+5
Thymidylate synthase 100_+50 99_+6 98_+5 77_+6*
Thymidine kinase 100_+6P 99+6 70-+5* 60-+5*
TMP kinase 100-+7q 91_+5 50_+4* 33_+3*
TDP kinase 100_+6 90_+5 99_+6 90_+6
d (ATP) pools 100_+5 109+_5
d (GTP) pools 100_+6 122+6’
d (CTP) pools 100-+5u 104_+8
d (TTP) pools 100_+4v, 114-+5
p< 0.001
26152 dpm 0.868 OD units 1179 dpm
4851 dpm 92551 dpm 1891 dpm
7461 dpm 0.121 OD units 6.17 pmol
47804 dpm 76058 dpm 5.27 pmol
4239 dpm 0.392 mol citrulline 6.87 pmol
1502 dpm 1.064 mol N-carbamyl aspartate 6.94 pmol
6400 dpm 18463 dpm
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DNA Studies
After deoxyribonucleoside triphosphates were extracted, 25 levels were determined by the method of Hunting
and Henderson 26 with calf thymus DNA, E. coli DNA polymerase I, non-limiting amounts of the three
deoxyribonucleoside triphosphates not being assayed, and either 0.4 mCi of (3H-methyl)-dTTP or (5-3H)
dCTP. The effects of compounds 2 and 3 on DNA strand scission was determined by the methods of Suzuki
et a/.27, Pera et al.28 and Woynarowski et al.29. L1210 lymphoid leukemia cells were incubated with 10 Ci
[methyl-3H]-thymidine (84.0 Ci/mmol) for 24 hr at 37C. L1210 cells (107) were harvested and then
centrifuged at 600 g X 10 min in PBS. They were later washed and suspended in ml of PBS. Lysis buffer
(0.5 ml; 0.5 M NaOH, 0.02 M EDTA, 0.01% Triton X-100 and 2.5% sucrose) was layered onto a 5-20%
alkaline-sucrose gradient (5 ml; 0.3 M NaOH, 0.7 KC1 and 0.01 M EDTA); this was followed by 0.2 ml of
the cell preparation. After the gradient was incubated for 2.5 hr at room temperature, it was centrifuged at
12,000 RPM at 20C for 60 min (Beckman rotor SW60). Fractions (0.2 ml) were collected from the bottom
of the gradient, neutralized with 0.2 ml of 0.3 N HC1, and measured for radioactivity.
Table 3: Effects of Tetrakis-g- {N-[(trimethylamineboryl)-carbonyl]-L-phenylalanyl-carboxylato}-bis-{N-
[(trimethylamineboryl)-carbonyl]-L-phenylalanine} Dicopper (II) (3) on L120 Leukemia Cell Metabolism In
Vitro Over 60 Min. Percent of Control (mean + s.d.)
(N=4)
Assay Control 25 gM 50M 100tM
DNA synthesis 100_+5a 85+6 80_+5* 62_+4*
RNA synthesis 100_+6b 64_+5* 59_+5* 31_+3"
Protein synthesis 100_+5c 112_+7 116_+8 112_+5
DNA polymerase cz 100_+6d 73_+5* 65_+6* 46_+5*
rRNA polymerase 100-+4e 127_+6’ 120_+5 113_+5
mRNA polymerase 100_+7f 82_+5 79_+6* 70_+4*
tRNA polymerase 100+7g 99_+5 89_+7 85_+5
Ribonucleoside diphosphate reductase 100_+5h 102_+5 99_+6 90_+6
Dihydrofolatereductase 100_+5 133_+6 80_+6 59_+5*
De novo purine synthesis 100_+5J 106_+6 67_+5* 38_+4*
PRPP amido transferase 100_+6k 67_+7* 44_+4* 31_+4"
IMP dehydrogenase 100_+51 58_+5* 49_+4* 36_+4*
Carbamyl phosphate synthetase 100_+7rn 110_+6 106_+5 104_+6
Aspartatetranscarbamylase 100_+6n 97_+6 97_+5 95_+6
Thymidylate synthase 100_+5 104_+5 92_+5 78_+5"
Thymidine kinase 100-+6P 49_+6* 48_+5* 42_+5*
TMP kinase 100_+7q 42_+6* 31_+5’ 28_+4*
TDP kinase 100_+6 101_+6 86_+5 83_+5
d (ATP) pools 100_+5 104_+4
d (GTP) pools 100_+6 123_+5"
d (CTP) pools 100_+5u 104_+5
d TTP ools 100_+4v 104_+3
*p< 0.001
26152 dpm 0.868 OD units
4851 dpm 92551 dpm
7461 dpm 0.121 OD units
47804 dpm 76058 dpm
4239 dpm 0.392 mol citrulline
1502 dpm 1.064 mol N-carbamyl aspartate
6400 dpm 18463 dpm
2744 dpm 1317 dpm
1179 dpm
1891 dpm
6.17 pmol
5.27 pmol
6.87 pmol
6.94 pmol
Thermal calf thymus DNA denaturation studies, changes in ct-DNA U.V. absorption from 220-340 nm, and
ct-DNA viscosity studies were conducted after incubation of compounds 2 and 3 at 100 laM at 37C for 24 hr
30
L210 DNA-topoisomerase II was isolated by the method of Miller, et al.31. The 170 kDa topoisomerase II is
present in the final preparation using the following procedures. All steps were carried out at 0-4C. L120
cells (2 x 108) were collected by centrifugation (500 x g for 5 min.), washed twice with PBS and resuspended
in buffer solution containing 0.25 M sucrose, 20 mM potassium phosphate (pH 7.5), 2 mM MgC12, mMM.C. Miller, III, A. Sood et al. Metal-Based Drugs
spermidine, 0.1 mM EDTA, 0.1 mM phenylmethyl sulfonyl fluoride (PMSF), and mM NaS205 at 4C.
Cell membranes were lysed using a Dounce homogenizer following the addition of Triton X-100 at a volume
equivalent to 1/100th the total cell suspension’s volume.
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Figure 1. L 1210 DNA Strand Scission Induced by 24 Hour Incubation with Compound 2.
Trypan blue staining of nuclei was used to determine complete cell lysis microscopically. An equal volume
of buffer containing 1.75 M sucrose was added to the cell suspension and mixed by gently swirling. After
mixing, the total volume was loaded on a sucrose cushion [1.4 M sucrose, 20 mM potassium phosphate (pH
7.5), 5 mM MgCI2, mM dithiothreitol (DTT), 0.1 mM EDTA, and mM PMSF] and centrifuged at
18,000 rpm for 45 min at 4C. The sucrose cushion was removed via vacuum aspiration and the remaining
pellet was resuspended in buffer containing 20 mM potassium phosphate (pH 7.5), 2 mM MgCI2, mM
dithiothreitol (DTT), 0.1 mM EDTA, and mM PMSF, mM [3-mercaptoethanol, 10% glycerol, and 100
mM NaC1. The suspension was incubated at 4C for 30 min. The process was repeated with buffers
containing increasing concentrations of NaC1 up to 400 mM. The supernatants containing enzyme activity
were used for assays. The effects of compounds 2 and 3 on isolated DNA topoisomerase II activity was
determined by the method of Miller et al.. Reactions containing 0.05 M Tris (pH 7.5), 0.1 M KC1, 0.01 M
MgCI2, 30 ktg/ml bovine serum albumin, 0.5 mM EDTA, 1.0 mM DTT, 1.0 mM ATP, 0.1 lag knotted
DNA (isolated by the method of Liu and Davis 32), 1U L1210 topoisomerase II and drugs were prepared. The
samples were allowed to incubate at 37C for h and then stopped by the addition of stop buffer [50% w/v
sucrose, 0.5% w/v sodium dodecylsulfate (SDS), and 0.25% w/v bromophenyl blue]. Each sample was run
for 18 h using a 0.7% agarose gel, in electrophoresis buffer (pH 8.0) [90 mM Tris, 2 mM EDTA, 90 mM
boric acid], on a Gibco BRL Horizon 11 X 14 electrophoresis apparatus at 23v. VP-16 (etoposide) was used
as an internal standard inhibitor for DNA topoisomerase II assay. Photographs of gels were made by
illumination of gels on a U.V. light table using Polaroid 667 film. Densitometric analysis was performed by
the method of Hofmann, et al.33 using a GS 300 Transmittance Reflectance Scanning Densitometer and the
GS 365 Densitometry Program (version 2) for personal computers (Hoefer Scientific Instruments, San
Francisco, CA). Photographs of agarose gels were scanned by the densitometer, in reflectance mode,
perpendicularly to the direction of DNA migration, aligned with the unknotted DNA bands. To standardize
the quantification of unknotted DNA, known amounts of completely unknotted P4 DNA were subjected to
electrophoresis and photographed.Vol. 5, No. 1, 1998 The Synthesis and Antitumor Activity ofthe Sodium Salt and Copper (II) Complex
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Figure 2. L1210 DNA Strand Scission Induced by 24 Hour Incubation with Compound 3.
The area under the curves corresponding to unknotted DNA bands were calculated using the densitometry
software package. Data were plotted as percent of enzyme control. ICs0 values were calculated by non-linear
regression analysis of plotted data using Prism(R), version 2 (GraphPad Software Inc., San Diego, CA).
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Figure 3: The Inhibition of L 1210 Topoisomerase II Activity In Vitro by Dipeptides and Metal Complexes
ofAmine Carboxyborane Adducts.
Statistical Analysis
Data as percentage of control is displayed in tables and figures as the means _+ standard deviations. N is the
number of samples per group. The Student’s "t"-test was used to determine the probable level of significance
(p) between test samples and control samples.
RESULTS AND DISCUSSION
Chemistry
The sodium salt 2 was quickly formed in the presence of sodium hydroxide. The production of side products
was noted which contributed to the lower than expected yield. The copper (II) complex was successfully
synthesized using IR-120 cation exchange resin charged with the desired cation. Ion exchange proceeded by
elution of a solution of the sodium salt 2 through a column of ion exchange resin. The structures and purity
of the compound were confirmed and elemental analysis, melting points, and both 1H-NMR and infrared
spectroscopy are reported. Attempts to form complexes by mixing methanolic solutions of carboxyborane
sodium salts with methanolic solutions of metal chloride salts were unsuccessful. The synthesis of sodium
N-[(trimethylamine-boryl)}-L-phenylalanine using sodium hydroxide provided an adequate yield of 47.4%;
however, the appearance of additional reaction products was apparent by TLC. It is possible that the reaction
conditions in the presence of sodium hydroxide may be caustic. After the initial reaction, only a slight
amount of starting material and a large proportion of product were visible by TLC. Column chromatography
proved a greater problem in that two impurities with similar Rf values with respect to the desired product
were apparent in the related fractions. It was not possible to remove these impurities by silica gel columnVol. 5, No. 1, 1998 The Synthesis and Antitumor Activity ofthe Sodium Salt and Copper (II) Complex
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chromatography as more of these impurities were generated with subsequent elutions. The formation of
impurities during silica gel chromatography was possibly due to the acidity of the stationary phase which may
facilitate protonation and rearrangement of the carboxyborane to boric acid as described by Sood, et al. 36, or
hydrolysis of the amide and/or ester linkages in the dipeptide.
Initial attempts to synthesize metal complexes of carboxyborane adducts followed the method ofNorwood et
al. 37,38 in which the methanolic solution of sodium salts were added to methanolic solutions of metal
chlorides. When applied to the study, a mixture of impurities were present at each stage of Norwood’s
procedure and purification was not possible. However, the use of IR-120 cation exchange resin provided a
more successful means to synthesis tetrakis-la-{N-{(trimethylamineboryl)-carbonyl-L-phenylalanine-
carboxylato}-bis-[N- (trimethylamine-boryl)- carbonyl] L]phenylalanine} dicopper(II) 3 without the need for
further purification. The synthesis of other metal complexes using ion exchange resin was not pursued due to
the limited amount of starting materials remaining after multiple attempts at metal complexation using the
Norwood method.
Antitumor Activity
Synthesized compounds demonstrated in vitro cytotoxicity primarily in suspended tumor cell lines (e.g,
murine L1210 lymphoid leukemia, human Tmolt3 T cell acute lymphoblastic leukemia, and HeLa-S
suspended human uterine cervical carcinoma) with variable activity in human solid tumor cell cultures.
Murine L1210 cytotoxicity assays demonstrated good activity for compound 2 (EDs0 2.68 tg/ml) which
was more effective than the parent 1 (EDs0 3.34 lag/ml)35. Rat osteogenic sarcoma UMR-106 activity was
noted for only compound 3 (EDs0 3.24 lag/ml). Against the growth of Tmolt3 only the parent 1 was active
(EDs0 1.31 g/ml). Compounds 2 (EDs0 2.37 lag/ml) and 3 (EDs0 1.91 lag/ml) were active against
human HeLa-S suspended cervical carcinoma growth while the parent compound was inactive. In contrast
compounds 1 (EDs0 3.38 lag/ml)and 2 (EDs0- 1.82 lag/ml) were active against solid HeLa cervical
carcinoma growth while compound 3 was inactive. The growth of KB nasopharynx was reduced by
compound 1 (EDs0 1.99 ktg/ml) alone. Only compound 3 (EDs0 3.22 lag/ml) effectively reduced SW480
colorectal adenocarcinoma cell growth. Against MB9812 bronchogenic lung growth, compounds 2 (EDs0
1.33 tg/ml) and 3 (EDs0 3.84 lag/ml) demonstrated activity while the parent was inactive. Compound 2
(EDs0 2.97 lag/ml) alone inhibited the growth of lung carcinoma A549, while only compound 3 (EDs0
2.39 g/ml) was effective against A431 epidermoid carcinoma growth. None of the compounds tested were
active against the growth ofHCT-8 ileum or HS-683 glioma [Table ].
The sodium salt and the copper (II) complex of N-[(trimethylamineboryl)-carbonyl]-L-phenylalanine were
effective cytotoxic agents against the growth of a variety of rodent and human tumor cell lines. A wide
variability was demonstrated with respect to which of these agents were the most active in a given screen.
The copper (II) complex 3, however, was not necessarily the most effective cytotoxic agent against each cell
line. This indicated that metal complexation by the phenylalanine derivative does not necessarily improve
cytotoxicity for certain cell lines.
Sodium N-[(trimethylamine- boryl)-carbonyl]-L-phenylalanine 2 and tetrakis--{N-[(trimethylamineboryl)
-carbonyl]-L-phenylalanyl-carboxylato}-bis-{N-[(trimethylamine-boryl)-carbonyl]-L-phenyla!anine} dicopper
(II) 3 were examined for their effects on L1210 cell nucleic acid and protein metabolism at 25, 50, and 100
[Tables 2 and 3]. The synthesis of L1210 DNA and RNA was significantly inhibited by compounds 2 and 3
in a concentration dependent manner, with maximal inhibition at 100 M. DNA synthesis was reduced 48
and 38% by compounds 2 and 3, respectively, at 100 laM. RNA synthesis was reduced 25 and 69% by
compounds 2 and 3, respectively, at 100 laM. Both compounds significantly inhibited DNA polymerase
activity at all concentrations employed, with greater than 50% inhibition at 100 t,tM. Compounds 2 and 3
were most effective in inhibiting purine de novo synthesis with a greater than 50% reduction at 25 laM for
compound 2 and at 100 laM for compound 3. Both PRPP amido transferase and IMP dehydrogenase
activities were reduced greater than 50% at drug concentrations of 50 and 100 M, respectively, by compound
2 and at 50 tM by compound 3 for both activities. These compounds were also able to affect thymidine
kinase and TMP kinase activities causing significant reduction in both enzyme activities at 50 laM for
compound 2 and greater than 50% reduction in both enzyme activities at 25 laM for compound 3. These
compounds did not affect L1210 deoxynucleotide pool levels other than a significant increase in d(GTP) levels
of22% and 23% by compounds 2 and 3, respectively, at 100 tM concentration.
Compounds 2 and 3 also demonstrated the ability to cause moderate L1210 strand scission [Fig. and 2].
This was indicated by the increase in low molecular weight (fragmented) DNA distributed throughout the
alkaline sucrose gradients and a reduction of higher molecular weight double stranded DNA compared to the
control. The ct-DNA U.V. absorption did not change after incubation for 24 hours with compounds 2 or 3.
This indicated no change in the helical structure ofDNA and that the agents did not chemically interact with
the DNA bases. There were no effects on U.V. absorption from 220 to 340 nm after 24 hour incubations with
compounds 2 or 3. This suggested that these agents do not alkylate DNA nucleotide bases. There was no
change in the thermal denaturation Tm values after 24 h incubation with the drugs, indicating no intercalation
between DNA base pairs had occurred. The ct-DNA viscosity studies demonstrated less time was required to
move through the reservoirs. Such an increase in flow rate suggested DNA viscosity was reduced by the
agents. The ability of compound 2 and 3 to reduce DNA viscosity is consistent with their ability to cause
moderate DNA strand scission.M.C. Miller, III, A. Sood et al. Metal-Based Drugs
Compounds 1 3 were evaluated for their mode of action as LI:I0 DNA topoisomerase II inhibitors [Fig. 3].
Only the copper complex 3 demonstrated inhibitory activity at 100 laM concentration. Compound 3
demonstrated concentration dependent inhibitory effects on L1210 topoisomerase II activity as evaluated by
densitometry, affording an ICs0 value of 29 tM. In comparison the prototypical topoisomerase II inhibitor
VP-16 which exhibited an ICs0 value of 22 laM.
In summary, mode of action studies on compound 2 primarily affected DNA synthesis at 100 tM while
compound 3 had a greater effect on RNA synthesis. The de novo purine synthetic pathway appeared to be an
important target for both compounds. Compound 2 preferentially reduced IMP dehydrogenase activity at 25
laM. In contrast, compound 3 markedly inhibited thymidine kinase and TMP kinase at 25 l-tM. At higher
concentrations both compounds had their greatest effects on the purine pathway regulatory enzymes, PRPP
amido transferase and IMP dehydrogenase, suggesting that inhibition of purine de novo synthesis is important
in causing cytotoxicity. The magnitude of reduction afforded by compounds 2 and 3 on regulatory enzymes
was sufficient to account for the observed reduction in DNA and RNA syntheses. In comparison, the parent
compound 1, also significantly reduced DNA and RNA syntheses. In contrast to compounds 2 and 3,
however, the parent compound had its greatest inhibitory effects on rRNA polymerase and ribonucleoside
reductase activities 34. The moderate effect of these compounds on double stranded DNA strand scission
suggested that these compounds may cause DNA fragmentation but there was little evidence that the bases of
DNA were the direct target of the agents. Copper (II) complexation to form compound 3 did improve the
compound’s ability to inhibit L120 DNA topoisomerase II activity compared to the parent compound which
should improve the ability to inhibit DNA synthesis and cause cell death.
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